ORLANDO, Florida ― Initiating unobserved buprenorphine induction to treat opioid dependence may help lower barriers to care in this population, new research suggests. Results from an observational ...

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet ...

Please provide your email address to receive an email when new articles are posted on . Patients with untreated opioid use disorder responded well to a high-dose induction of buprenorphine in the ED, ...

As one of the few evidence-based treatments shown to decrease mortality, buprenorphine use has grown in the United States and abroad. Buprenorphine is a first line option for opioid use disorder shown ...

Combined data from the Induction, STabilization, Adherence and Retention Trial (ISTART) (Study OX219-006) and Study OX219-007, in 1068 opioid dependent patients, showed that over 90% of patients ...

In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.

High-dose buprenorphine therapy, provided under emergency department care, is safe and well tolerated in people with opioid use disorder experiencing opioid withdrawal symptoms, according to a study ...

RALEIGH, N.C., May 2, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug ...

Administering high-dose buprenorphine in the emergency department (ED) to individuals with untreated opioid use disorder (OUD) is safe, well tolerated, and may help get more patients into treatment ...

All of our services are outpatient - office based treatment. Our patients are initially seen to determine if they are suffering from Opioid Use Disorder and if they are appropriate for Buprenorphine ...

SAN DIEGO--(BUSINESS WIRE)--Millennium Health, an accredited specialty laboratory specializing in medication monitoring and drug testing, is collaborating with investigators from the University of ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.